Prevention of onset in an insulin-dependent diabetes mellitus model, NOD mice, by oral feeding of Lactobacillus casei. APMIS 105: [643][644][645][646][647][648][649] 1997.The effects of Lactobacillus casei (LC) on the onset of diabetes in an insulin-dependent diabetes mellitus model, nonobese diabetic (NOD) mice, were examined. From the age of 4 weeks, female NOD mice were fed a diet of either standard laboratory chow (n= 12) or the same chow containing 0.05% weight heat-killed cells of LC (n= 12), and the onset of diabetes was thereafter recorded. The incidence of diabetes in the control group (10112) was significantly higher than that in the LC-treated group (31 12) (p
Yokokura, T. Effect of oral administration of Lactobacillus casei on alloxan-induced diabetes in mice. APMIS 105: [637][638][639][640][641][642] 1997.The effects of Lactobacillus casei (LC) on the onset of alloxan (AXN)-induced diabetes in 7-week-old BALBic mice were examined. It was observed that the mice given a diet containing 0.1%1 or 0.05% LC or orally administered LC showed significantly decreased incidence of diabetes induced by intravenous injection of AXN and that the plasma glucose level was slightly lower than that in the control group.The body weight in the LC-treated groups was higher than that in the control group, although the food intake weights were almost the same. Pathological analysis revealed that the XXN-induced disappearance of insulin-secreting p-cells in the islets of Langerhans was strongly inhibited in the LCtreated groups. It was also shown that the serum nitric oxide level was maintained at a normal level in LC-treated mice, whereas the level in the control group was increased by AXN administration. Taken together, these findings suggest that oral administration of LC to AXN-treated BALBic mice contributed to the reduction of diabetes and the increase in plasma glucose level.
Aberrant crypt foci (ACF)induced in the distal colon of F344 male rats, 4, 8, 12 and 35 weeks after the first administration of 1, 2‐dimethylhydrazine‐2HCl (DMH) were examined to determine whether a correlation exists between the nature of goblet cell mucin and the number of crypts (crypt multiplicity) comprising the ACF. According to the ACF score calculated from the results of the qualitative observation of sulfomucins (SuMs) and sialomucins (SiMs), the ACF in the 4th week showed a weak correlation between the nature of the mucus and crypt multiplicity, and the ACF of each class showed similar mucous profiles. From the 8th week, a significant difference (P<0.01) was recognized between the ACF consisting of 3 crypts or less and those consisting of 4 crypts or more. The proportion of crypts with SiM predominance showed a decrease in the 8th.week in the ACF consisting of 1 crypt and in the 12th week in the ACF consisting of 2 or 3 crypts, implying a recovery tendency. The ACF consisting of more than 4 crypts showed little change over time, retaining the tendency of SiM predominance. Ulex europaeus agglutinin‐I (UEA‐I) lectin‐positive crypts appeared in the ACF. This finding was significantly more prominent (P< 0.001) in the ACF with SiM predominance than in the ACF with SuM predominance at each experimental period, and in the 12th week after the first administration of DMH, the incidence of ACF with UEA‐I‐reactive mucin was decreased in the ACF groups consisting of 3 crypts or less, compared with the ACF groups consisting of 4 or more crypts.These results suggest that the biological quality of mucus in ACF consisting of 4 or more crypts is different from that in ACF consisting of 3 crypts or less. This difference should be considered when ACF are used as an intermediate biomarker of colon cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.